Target Name: MCEE
NCBI ID: G84693
Review Report on MCEE Target / Biomarker Content of Review Report on MCEE Target / Biomarker
MCEE
Other Name(s): Methylmalonyl-CoA epimerase, mitochondrial | Methylmalonyl-CoA epimerase | DL-methylmalonyl-CoA racemase | MCE | GLOD2 | methylmalonyl-CoA epimerase | MMCE | MCEE_HUMAN | methylmalonyl CoA isomerase | glyoxalase domain containing 2

Methylmalonyl-CoA Epimerase: A Potential Drug Target and Biomarker for Diseases

Methylmalonyl-CoA epimerase (MCEE) is a protein that is expressed in the mitochondria and is involved in the metabolism of fatty acids. It is a key enzyme in the citric acid cycle, also known as the Krebs cycle or TCA cycle, which is a central metabolic pathway that generates energy in the form of ATP from food molecules. MCEE is also a key enzyme in the 2-step malonylation of fatty acids, which is the final step in the citric acid cycle and results in the production of ethyl-CoA , which is then converted to acetyl-CoA and carbon dioxide.

MCEE is a 23-kDa protein that is expressed in the mitochondria and is involved in the metabolism of fatty acids, particularly in the production of ethyl-CoA from fatty acids. It is a key enzyme in the 2-step malonylation of fatty acids and is located in the mitochondria, where it is part of the inner mitochondrial membrane. MCEE is a subunit of the complex I (also known as the inner mitochondrial membrane sytome) and is composed of three尾 subunits and one 伪 subunit.

MCEE is regulated by multiple factors, including oxygen, carbon dioxide, and fatty acids. It is activated by the presence of oxygen and carbon dioxide and is inhibited by the presence of fatty acids. MCEE is also regulated by other molecules, including NAD+, FAD , and ATP.

MCEE is a potential drug target because of its involvement in the production of ethyl-CoA, which is a known risk factor for a variety of diseases, including cancer, heart disease, and neurodegenerative diseases. In addition, MCEE is also involved in the production of other molecules that are associated with the development of these diseases, such as IPv6 and IPv4, which are known risk factors for cancer and neurodegenerative diseases, respectively.

MCEE is also a potential biomarker for these diseases, as its levels are often elevated in the blood and urine of patients with these conditions. For example, studies have shown that the levels of MCEE are elevated in the blood and urine of patients with cancer, heart disease, and neurodegenerative diseases. This suggests that MCEE may be a useful biomarker for these conditions.

In addition to its potential clinical applications, MCEE is also a potential target for drug development. By inhibiting the activity of MCEE, drugs can be developed that treat a variety of diseases, including cancer, heart disease, and neurodegenerative diseases. This is because MCEE is involved in the production of many molecules that are associated with the development of these conditions, so inhibiting its activity can lead to the production of compounds that have a beneficial effect on these conditions.

In conclusion, MCEE is a protein that is expressed in the mitochondria and is involved in the metabolism of fatty acids. It is a key enzyme in the citric acid cycle and is also involved in the 2-step malonylation of fatty acids. MCEE is a potential drug target and biomarker for a variety of diseases, including cancer, heart disease, and neurodegenerative diseases. Its inhibition could lead to the production of compounds that have a beneficial effect on these conditions. Further research is needed to fully understand the role of MCEE in the development and treatment of these diseases.

Protein Name: Methylmalonyl-CoA Epimerase

Functions: Methylmalonyl-CoA epimerase involved in propionyl-CoA metabolism

The "MCEE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCEE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MCEMP1 | MCF2 | MCF2L | MCF2L-AS1 | MCF2L2 | MCFD2 | MCFD2P1 | MCHR1 | MCHR2 | MCHR2-AS1 | MCIDAS | MCL1 | MCM10 | MCM2 | MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6